We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
British biotech Circassia has announced the death of its allergy programme following a second key trial failure, choosing to focus all of its efforts on its respiratory business instead.